Who are Norepinephrine and Vasopressin for Rescue's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): norepinephrine+vasopressin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/norepinephrine-and-vasopressin-for-rescue.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Norepinephrine and Vasopressin for Rescue — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Norepinephrine and Vasopressin for Rescue (Norepinephrine and Vasopressin for Rescue) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vasopressor combination. Area: Critical Care / Cardiovascular.

phase 3 Vasopressor combination Alpha-1 adrenergic receptor, beta-1 adrenergic receptor, V1 vasopressin receptor Critical Care / Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Norepinephrine and Vasopressin for Rescue (Norepinephrine and Vasopressin for Rescue) — Hospital do Coracao. This combination therapy uses norepinephrine and vasopressin to increase blood pressure and peripheral vascular resistance in patients with refractory hypotension or shock.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Norepinephrine and Vasopressin for Rescue TARGET	Norepinephrine and Vasopressin for Rescue	Hospital do Coracao	phase 3	Vasopressor combination	Alpha-1 adrenergic receptor, beta-1 adrenergic receptor, V1 vasopressin receptor
norepinephrine+vasopressin	norepinephrine+vasopressin	Peking Union Medical College Hospital	marketed	Vasopressor combination	Alpha-1 adrenergic receptor, beta-1 adrenergic receptor, vasopressin V1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vasopressor combination class)

Hospital do Coracao · 1 drug in this class
Peking Union Medical College Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Norepinephrine and Vasopressin for Rescue — Competitive Intelligence Brief. https://druglandscape.com/ci/norepinephrine-and-vasopressin-for-rescue. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab